Blockade Medical has received 510(k) clearance from the US Food and Drug Administration (FDA) and European CE Mark for two additions to the Barricade Coil system, with enhanced framing and complex finishing capabilities.
The Barricade Coil system is designed for the endovascular embolisation of intracranial aneurysms and other neurovascular abnormalities such as arteriovenous malformations and arteriovenous fistulae.
The comprehensive bare platinum coil line is available in framing, filling and finishing shapes.
The system is also intended for vascular occlusion of blood vessels within the neurovascular system to permanently obstruct blood flow to an aneurysm or other vascular malformation and for arterial and venous embolisations in the peripheral vasculature.
State University of New York Buffalo department of neurosurgery vice-chairman and associate professor Dr Adnan Siddiqui said: "The enhanced first loop design of the new Barricade Framing Coil will expand the types of aneurysms I can now treat with the Barricade Coil system."
The company received CE Mark clearance in July 2012 and the FDA 510(k) clearance in March 2013 for the Barricade Coil system.
Blockade Medical president and chief technology officer Dave Ferrera said: "As we develop future coil and endoluminal technologies, we will continue to develop products that will make a positive clinical impact for clinicians and patients while also delivering compelling economic savings to the health care system."
According to GlobalData estimates, the US embolic systems market was valued at $224.8m in 2012 and is expected to grow at a CAGR of 7.1% to reach $363.3m by 2019.